Ocumetics Technology Corp. (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO) has announced the start of patient recruitment for Group Two of its ongoing human clinical study of the Ocumetics Lens, a next-generation accommodating intraocular lens designed to potentially eliminate the need for corrective lenses. The clinical facility in Mexico City, which successfully performed Group One surgeries in Fall 2025, is now identifying and recruiting eligible patients for surgeries targeted for Fall 2026.
The Group Two study represents a pivotal advancement in the clinical development of the Ocumetics Lens. While Group One focused solely on safety, this next phase will evaluate both safety and the near-and distance-vision performance of the lens. According to the company, patients will receive the latest-generation Ocumetics Lens implanted with an enhanced delivery system, reflecting ongoing technological improvements.
Dean Burns, President and CEO of Ocumetics, expressed enthusiasm about the progress: “We are extremely excited to begin the process of moving into our larger Group Two study. Commencement of this study represents another important milestone in the continued clinical development of the Ocumetics Lens. Recruiting will be completed soon and we will schedule surgical dates shortly thereafter.”
In addition to the start of Group Two, the company is approaching a significant data milestone: Group One patients are reaching their 12-month follow-up visits. This longer-term clinical data will provide crucial insights into the lens’s safety and performance over time. The Group One outcomes reportedly met and exceeded company expectations, offering valuable information on safety, performance, and handling.
“We are particularly excited to reach the 12-month milestone for our Group One patients, which will provide an important body of longer-term clinical data as we continue to advance the Ocumetics Lens,” said Burns. “At the same time, the Group Two study represents an important step forward as we introduce our next-generation Ocumetics Lens together with our next-generation lens delivery system. This combination represents the continued evolution of our technology and our commitment to developing a truly differentiated solution for patients seeking improved vision across a broader range of distances.”
The Ocumetics Lens is designed to fit within the natural lens compartment of the eye and use the eye’s natural muscle activity to shift focus from distance to near, potentially providing clear vision at all distances without glasses or contact lenses and without perceptible time lag. This technology could significantly impact the field of ophthalmology by offering an alternative to traditional corrective lenses.
The initiation of Group Two surgeries is a critical step in the clinical validation of this innovative lens. As the company advances through clinical trials, the accumulation of safety and performance data will be essential for regulatory approvals and eventual commercialization. The outcomes of these studies will determine whether this technology can fulfill its promise to transform vision correction.
For more information about Ocumetics and its clinical programs, visit the company’s profile on NewMediaWire.
